Therefore, LCP1 has promising application prospects as a noninvasive marker of NAFLD/NASH, which is expected to replace liver biopsy to distinguish NAFLD disease stage and detect liver fibrosis degree. The gene discussed is LCP1; the disease is metabolic dysfunction-associated steatohepatitis.